Foghorn therapeutics to participate in two upcoming investor conferences in september

Cambridge, mass., aug. 28, 2024 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 wells fargo healthcare conference and presentation at the morgan stanley 22nd annual global healthcare conference. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking